Literature DB >> 25750508

Preventing COPD exacerbations: new options for a crucial and growing problem.

Jeffrey L Curtis1, Carlos H Martinez1.   

Abstract

Entities:  

Year:  2014        PMID： 25750508      PMCID： PMC4350387     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


× No keyword cloud information.
  65 in total

1.  Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation.

Authors:  Ivana Stanojkovic; Jelena Kotur-Stevuljevic; Branislava Milenkovic; Slavica Spasic; Tatjana Vujic; Aleksandra Stefanovic; Aleksandra Llic; Jasmina Ivanisevic
Journal:  Respir Med       Date:  2011-10       Impact factor: 3.415

2.  Deaths: final data for 2008.

Authors:  Arialdi M Miniño; Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek
Journal:  Natl Vital Stat Rep       Date:  2011-12-07

Review 3.  Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial.

Authors:  James K Stoller; Ralph J Panos; Samuel Krachman; Dennis E Doherty; Barry Make
Journal:  Chest       Date:  2010-07       Impact factor: 9.410

4.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

5.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Authors:  W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

6.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

7.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

Authors:  Bartolome Celli; Marc Decramer; Steven Kesten; Dacheng Liu; Sunil Mehra; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

8.  Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Authors:  Margaret K Pasquale; Shawn X Sun; Frank Song; Heather J Hartnett; Stephen A Stemkowski
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-11-01

Review 9.  Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement.

Authors:  Paul Jones; Marc Miravitlles; Thys van der Molen; Karoly Kulich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-16

Review 10.  Indacaterol: a comprehensive review.

Authors:  Andrea Rossi; Guido Polese
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-07-25
View more
  1 in total

1.  Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.

Authors:  Maryam Navaie; Bartolome R Celli; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.